StockData
Dogwood Therapeutics, Inc. logo

Dogwood Therapeutics, Inc. (DWTX) shareholders

DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.08+0.02 (+1.89%)

Close on Nov 17, 2026Market cap $36.71MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
11.3%
4M of 34M shares
Institutional holders
15
5 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
CK Life Sciences Int'l., (Holdings) Inc.
Joint filing with Sealbond Limited (67.80%), Conjoint Inc. (7.40%)
28,763,33175.20%13D (active) amendmentOct 26, 2026
Steven Boyd
Joint filing with Armistice Capital, LLC (9.99%)
3,384,7989.99%13G (passive) amendmentJun 30, 2026
Armistice Capital, LLC
Joint filing with Steven Boyd (9.99%)
3,343,1209.99%13G (passive)Mar 31, 2026
Sealbond Limited
Joint filing with CK Life Sciences Int'l., (Holdings) Inc. (15.90%)
211,38315.90%13D (active) amendmentMar 12, 2025
Orca Capital AG115,7906.10%13G (passive)Mar 12, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of DWTXValueChange% of portfolio
Armistice Capital, LLC3,132,4869.22%$5.04M−147,5140.06%
Millennium Management LLC341,8141.01%$550.32KNew0.00%
Vanguard Capital Management LLC132,1540.39%$212.77K–0.00%
Geode Capital Management, LLC88,2980.26%$142.16K+8,8640.00%
Vanguard Fiduciary Trust Co62,7360.18%$101.01K–0.00%
BlackRock, Inc.28,5460.08%$45.96K+28,5160.00%
Northern Trust Corp23,7790.07%$38.28K–0.00%
Citadel Advisors LLC11,7420.03%$18.91KNew0.00%
Tower Research Capital LLC (TRC)3,0930.01%$4.98K−4,9740.00%
Morgan Stanley2,2220.01%$3.58KNew0.00%
UBS Group AG1,8600.01%$3.00K−5,2250.00%
Jones Financial Companies Lllp1600.00%$264New0.00%
Barclays PLC1570.00%$253New0.00%
Activest Wealth Management1200.00%$193–0.00%
Group One Trading, L.P.90.00%$14–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026154M11.3%5 / 23 / 30M0M
Q1 2026134M10.6%6 / 30 / 24M0M
Q4 2025100M0.2%2 / 32 / 40M0M
Q3 2025120M0.1%3 / 24 / 10M0M
Q2 2025100M0.1%1 / 23 / 40M0M
Q1 2025130M0.2%4 / 41 / 10M0M
Q4 2024100M0.1%10 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

7 funds held DWTX in Q2 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of DWTXValue% of fundAs of
Vanguard Extended Market Index Fund132,1540.39%$212.77K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund57,1630.17%$96.61K0.00%May 31, 2026
iShares Micro-Cap ETF26,6240.08%$42.86K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund13,0590.04%$22.07K0.00%May 31, 2026
Fidelity Total Market Index Fund2,2940.01%$3.88K0.00%May 31, 2026
1290 VT Micro Cap Portfolio1,8920.01%$3.05K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund8800.00%$1.49K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Gregory Scott DuncanCHIEF EXECUTIVE OFFICER, Director57,4610.17%Mar 6, 2026
Roger Michael GendreauCHIEF MEDICAL OFFICER––Mar 6, 2026
Ralph GrosswaldSVP OF OPERATIONS––Mar 6, 2026
Angela WalshChief Financial Officer3,0000.01%Mar 6, 2026
Inc. ConjointDirector, 10% owner24,664,97172.56%Oct 27, 2026
Ltd SealbondDirector, 10% owner28,763,33184.62%Oct 27, 2026
Life Sciences Intl (Holdings) Inc CKDirector, 10% owner––Oct 27, 2026
David R. KeeferDirector12,8080.04%Jun 17, 2026
John C. ThomasDirector1,0000.00%Jun 17, 2026
Richard James WhitleyDirector7000.00%Jun 17, 2026
La Rosa Abel DeDirector4,0000.01%Jun 17, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Ltd Sealbond
Director, 10% owner
Oct 26, 2026Award+4,098,360$1.22$5.00M25,920,693
Inc. Conjoint
Director, 10% owner
Nov 21, 2025Conversion+21,610,950––21,822,333
Inc. Conjoint
Director, 10% owner
Nov 21, 2025Conversion+2,842,638––2,842,638
William Pridgen
Director
Aug 21, 2023Buy+15,335$1.30$19.94K52,045
Gregory Scott Duncan
CHIEF EXECUTIVE OFFICER, Director
Aug 17, 2023Buy+25,000$1.25$31.25K57,461
Richard James Whitley
Director
Dec 8, 2022Sale−1,800$0.26$468700
Gregory Scott Duncan
CHIEF EXECUTIVE OFFICER, Director
May 23, 2022Buy+7,500$4.52$33.90K32,461
Angela Walsh
SVP OF FINANCE
May 23, 2022Buy+2,000$4.58$9.16K3,000
Richard James Whitley
Director
May 18, 2022Buy+500$4.53$2.27K2,500
William Pridgen
Director
May 18, 2022Buy+241$4.50$1.08K36,710
William Pridgen
Director
May 17, 2022Buy+13,450$4.38$58.91K36,469
William Pridgen
Director
Mar 29, 2022Buy+600$4.94$2.96K23,019
William Pridgen
Director
Mar 23, 2022Buy+2,197$5.46$12.00K22,419
William Pridgen
Director
Jan 27, 2022Buy+4,180$5.98$25.00K18,722
La Rosa Abel De
Director
Jan 7, 2022Buy+4,000$5.90$23.60K4,000
Richard James Whitley
Director
Jan 6, 2022Buy+1,800$5.72$10.30K2,000
David R. Keefer
Director
Jan 4, 2022Buy+5,000$5.80$29.00K5,000
John C. Thomas
Director
Jan 4, 2022Buy+1,000$5.65$5.65K1,000
William Pridgen
Director
Jan 3, 2022Buy+2,215$5.43$12.03K14,542
Richard James Whitley
Director
Dec 23, 2021Buy+200$5.73$1.15K200
William Pridgen
Director
Dec 21, 2021Buy+8,827$5.66$49.96K12,327
Gregory Scott Duncan
CHIEF EXECUTIVE OFFICER, Director
Dec 21, 2021Buy+5,000$5.52$27.60K24,961
William Pridgen
Director
Jul 7, 2021Buy+942$6.32$5.95K710,734
Gregory Scott Duncan
Chief Executive Officer, Director
Apr 6, 2021Buy+382$6.36$2.43K19,961
Gregory Scott Duncan
Chief Executive Officer, Director
Apr 5, 2021Buy+15,675$6.17$96.71K19,579
Gregory Scott Duncan
Chief Executive Officer, Director
Apr 5, 2021Buy+15,675$6.17$96.71K19,579
William Pridgen
Director
Jan 29, 2021Buy+3,500$7.47$26.15K3,500
Angela Walsh
VP of Finance
Jan 28, 2021Buy+1,000$7.30$7.30K1,000
David R. Keefer
Director
Jan 28, 2021Option exercise+1,602$7.80$12.50K7,808
William Pridgen
Director
Jan 28, 2021Option exercise+801$7.80$6.25K727,993
Gregory Scott Duncan
Chief Executive Officer, Director
Jan 6, 2021Option exercise+801$7.80$6.25K3,904
William Pridgen
Director
Dec 17, 2020Buy+1,500$11.98$17.97K727,192

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
0.33%
0M shares short
Days to cover
1.6
At 0M shares a day
Change since last report
+79.0%
From 0M shares
Short volume, 20 days
49.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Dogwood Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,762 shares on Oct 14, 2026 over the last 90 days.

See a number that looks wrong?